Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2352W HIGH $2.90
Volume
20.41 K
Value Traded
3.08 K
Short % Float
0.25%
Days to Cover
4.1
-0.98%Week
-18.39%1 Month
-20.83%3 Month
-64.3%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
54.05 M
EPS (TTM)
0.71
P/E Ratio
0.46
Ent. Value
171.96 M
Total Shares
166.51 M
Float Shares
48.43 M
Insiders
70.90%
Institutions
0.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALPS Catalyst Timeline
Dated clinical, regulatory and corporate events for ALPS Group Inc Ordinary Share
Past FDA Catalysts and PDUFA Decisions
How ALPS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
ALPS Group Inc is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ALPS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| autologous NK cell infusions | 2026-02-23 | Nine patients receiving autologous NK cell infusions demonstrated clinical tolerability with no reported dose-dependent toxic reactions, supporting the safety of the Company's proprietary culture protocol for NK cell production.Read More | Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture ProtocolRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALPS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ALPS for Q2 2026. | ||||
ALPS Institutional Ownership Trends
ALPS Short Interest
Shares sold short, counted twice a month.
0.25%
Short % of Float
of tradable shares sold short
118.9K
Shares Sold Short
-5.6% vs prior count
4.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
29.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALPS ranks across every disease it competes in
Competitive Position is a premium feature
See how ALPS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALPS News
-ALPS
Oct 30, 2026▼ 0%today
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
Alps Group Inc announced that shareholders approved a share consolidation at a one-for-five ratio, increasing authorized share capital. This change will take effect on November 9, 2026, reducing the number of outstanding shares while maintaining shareholder voting power. The company aims to enhance its market position through these adjustments.
Read more →-ALPS
Jun 9, 2026ALPS Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022 Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening
Alps Group Inc has announced the accreditation of its subsidiary MyGenome Sdn. Bhd. for Whole Genome Sequencing (WGS) under the rigorous MS ISO 15189:2022 standard. This achievement enhances the credibility and operational standards of MyGenome, enabling it to deliver genomic data that meets required benchmarks for clinical use. The accreditation places MyGenome among a limited number of Southeast Asian laboratories meeting international standards. This milestone is expected to broaden Alps’ market reach and support its goal of advancing precision medicine in the region.
Read more →-ALPS
May 19, 2026▼ -9%on this news· ran to -21% by day 3
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Alps Group Inc has received a notification from Nasdaq regarding a deficiency in maintaining the minimum bid price of $1.00 per share. The company has a compliance period of 180 days to address this issue, during which trading of its shares will not be affected. Alps Group is currently exploring options to regain compliance but acknowledges the uncertainty of achieving this.
Read more →-ALPS
Apr 17, 2026Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight
Alps Group Inc has appointed Mr. Hee H. Lee to its Board of Directors, expanding the board from five to six members. Mr. Lee, a former Partner at Ernst & Young, brings over 35 years of experience in financial reporting and governance. His role is expected to enhance the company's oversight in capital markets and support its strategic direction.
Read more →-ALPS
Feb 24, 2026Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell
Alps Group Inc has published a peer-reviewed case study demonstrating the safety and effectiveness of its autologous NK cell infusions. The study involved nine patients and showed positive results regarding clinical tolerability and cytotoxicity against cancer cells. The company's innovative culture method enhances the production of NK cells, potentially advancing immunotherapy accessibility.
Read more →-ALPS
Feb 23, 2026ALPS Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol
Alps Group Inc has announced positive results from a peer-reviewed case study published in SAGE Open Medical Case Reports, highlighting the safety and tolerability of their autologous Natural Killer (NK) cell infusions. The study involved nine patients who received NK cells cultured using an innovative, patent-pending method that enhances both purity and production efficiency. These findings not only support the clinical application of their NK cell therapy but also aim to make advanced immunotherapy more accessible and cost-effective. Future clinical investigations in larger populations are planned based on this data, affirming Alps Group's position in next-generation immune cell therapies.
Read more →-ALPS
Feb 5, 2026UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context otherwise requires, all references in this pro forma to "Globalink", "Pubco" and "Alps Holdco" refer to "Globalink Investment Inc, "Älp
Globalink Investment has entered into a merger agreement with Alps Holdco, which has been amended multiple times, culminating in a business combination expected to be completed on October 28, 2025. This includes a redomestication merger and an acquisition merger, where Alps Holdco will become a wholly-owned subsidiary of PubCo. The total consideration for this transaction amounts to $1.6 billion, paid in newly issued ordinary shares. The combined financial information reflects both companies' performances, but caution is advised in interpreting the pro forma results, as historical figures may not predict future performance accurately.
Read more →-ALPS
Jan 30, 2026ALPS Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
Alps Group Inc has announced an expansion of its exosome-related pipeline following preliminary findings on nebulized human umbilical cord mesenchymal stem cell-derived exosomes. The results, published in SAGE Open Medical Case Reports, indicate potential therapeutic benefits for patients with asthma and chronic obstructive pulmonary disease (COPD). Despite promising preliminary observational results, the company acknowledges the necessity of larger-scale controlled studies to validate the effectiveness and establish standardized treatment protocols. This development may indicate a shift from standard symptom management to disease-modifying therapy.
Read more →-ALPS
Jan 8, 2026Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer
Alps Group Inc has appointed Cheing Lye-Ping as Chief Financial Officer, effective January 5, 2026. Cheing brings over 30 years of finance and accounting experience, previously holding senior roles in both public and private companies. Her responsibilities will include developing the financial strategy and overseeing budgeting, analysis, and compliance. The CEO of Alps Group expressed excitement about this significant addition to the executive team as the company anticipates growth and new opportunities under her leadership.
Read more →-ALPS
Oct 31, 2025▲ +1696.5%on this newsshared move
Alps Announces Closing of Business Combination with Globalink Investment Inc.
Alps Group Inc. has successfully completed its business combination with Globalink Investment Inc., resulting in Alps Ordinary shares being listed on the Nasdaq under the ticker 'ALPS' effective October 31, 2025. This merger creates a combined company with an estimated enterprise value of approximately $1.6 billion and aims to redefine future healthcare through its focus on precision medicine. The company's headquarters will be located in Kuala Lumpur, Malaysia, and it will operate under the name of Alps Group Inc. CEO Tham Seng Kong emphasized the merger's significance in enhancing global healthcare solutions.
Read more →-ALPS
Jan 31, 2024▲ +1696.5%on this newsshared move
ALPS GLOBAL HOLDING BERHAD TO BECOME PUBLICLY TRADED THROUGH PROPOSED MERGER WITH GLOBALINK INVESTMENT INC.
Alps Global Holding Berhad has announced a merger with Globalink Investment Inc., aiming to become publicly traded under the name Alps Life Science Inc. The transaction, valued at approximately $1.6 billion, is expected to close in the second quarter of 2024. This merger positions Alps to enhance its role in personalized medicine and expand its market reach.
Read more →About ALPS Group Inc Ordinary Share
BIOPHARMAWATCH ELITE PLUS
Trade the next ALPS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime